Tramiprosate

Summary

Tramiprosate (CHEMBL149082) is a phase-3 clinical-stage small-molecule nootropic agent; indicated across 1 condition including alzheimer disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 3
• Chemistry: 139.18 Da · C3H9NO3S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL149082
Name	Tramiprosate
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	1646
ChEBI	CHEBI:1457
Molecular formula	C3H9NO3S
Molecular weight	139.18
InChIKey	SNKZJIOFVMKAOJ-UHFFFAOYSA-N

SMILES: C(CN)CS(=O)(=O)O

IUPAC name: 3-aminopropane-1-sulfonic acid

ChEBI definition: An amino sulfonic acid that is the 3-amino derivative of propanesulfonic acid.

Pharmacological roles (ChEBI): nootropic agent, anticonvulsant, GABA agonist, anti-inflammatory agent.

Other ChEBI roles (chemical / environmental): algal metabolite.

Also known as: Acamprosate related compound a, Homotaurine, NC-531, NC-758, NSC-77071, Tramiprosate, Tramiprosato, SID90340792, TRAMIPROSATE, SID8139961

Parent form; salt/anhydrous children: CHEMBL1256024, CHEMBL1256473

Patent coverage: 2,677 distinct patent families (8,332 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: GABA-A receptor; anion channel, GABA B receptor, Amyloid-beta precursor protein.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 4 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
O09028	6.52	IC50	300	nM	CHEMBL_ACT_1107124
O88871	5.7	IC50	2000	nM	CHEMBL_ACT_394652

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
Alzheimer disease	3	MONDO:0004975	MONDO:0004975

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE4	1
PHASE3	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05022186	PHASE4	UNKNOWN	The Effects of Cannabidiol and Homotaurine in Patients With Mild Cognitive Impairment
NCT00314912	PHASE3	UNKNOWN	Open-Label Extension of the Phase III Study With Tramiprosate (3APS) in Patients With Mild to Moderate Alzheimer’s Disease
NCT04378972	Not specified	COMPLETED	Anti-inflammatory Effect of Curcumin, Homotaurine, Vitamin D3 on Human Vitreous in Patients With Diabetic Retinopathy

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).